Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,293.93
+9.800.76%
Number of Gainers:4
Number of Losers:3
Number of Flat:- -
PE:- -
High:1,303.79
Open:1,281.56
Low:1,281.54
Close:1,284.13
Volume:77.09M
Turnover:5.70B
Market Cap:1.35T
Float Cap:1.30T

Loading ...

OverviewNews

InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly

TIPRANKS
·
Mar 29

INSILICO Enters Global Licensing and AI Drug Development Partnership with Eli Lilly

Stock News
·
Mar 29

Insilico Medicine Cayman Topco Says Collaboration Grants Lilly Exclusive Worldwide License for Development, Manufacturing and Commercialization of Oral Therapeutics in Preclinical Development

THOMSON REUTERS
·
Mar 29

Insilico Medicine Cayman Topco Announces Licensing and Drug Discovery Collaboration With Eli Lilly

THOMSON REUTERS
·
Mar 29

BRIEF-Eli Lilly To Sign $2 Bln Deal For AI Drug Development With Hong Kong Biotech Insilico Medicine - FT

Reuters
·
Mar 29

Eli Lilly to Sign $2Bn Deal for AI Drug Development With Hong Kong Biotech Insilico Medicine - FT

THOMSON REUTERS
·
Mar 29

Lilly Will Acquire Exclusive Rights to Sell a Glp-1 Drug for Diabetes From Insilico Medicine - FT

THOMSON REUTERS
·
Mar 29

Amgen says Repatha cuts first major cardiovascular events 31% in VESALIUS-CV subgroup

Reuters
·
Mar 29

BRIEF-Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients

Reuters
·
Mar 29

Amgen: Phase 3 Vesalius-Cv Clinical Trial Showed Repatha Reduced Risks of Heart Attack, Coronary Heart Disease Death, Ischemic Stroke

THOMSON REUTERS
·
Mar 29

Amgen: Repatha Cuts Risk of First Major Cardiovascular Event by 31% in High-Risk Patients Without Known Significant Atherosclerosis

THOMSON REUTERS
·
Mar 29

BRIEF-Eli Lilly Says Taltz And Zepbound Met Primary And All Key Secondary Endpoints For Statistical Superiority To Taltz Monotherapy At 36 Weeks

Reuters
·
Mar 29

Lilly Phase 3b trial shows Taltz plus Zepbound beats Taltz alone in psoriatic arthritis

Reuters
·
Mar 29

Phase 3B Data Presented at Aad Annual Meeting Show Lilly's Taltz (Ixekizumab) Plus Zepbound (Tirzepatide) Delivered Superior Efficacy for Adults With Psoriatic Arthritis and Obesity

THOMSON REUTERS
·
Mar 29

Eli Lilly - Taltz and Zepbound Met Primary and All Key Secondary Endpoints for Statistical Superiority to Taltz Monotherapy at 36 Weeks

THOMSON REUTERS
·
Mar 29

Pfizer Oncology Wins Raise Questions On Valuation Gap And Future Revenues

Simply Wall St.
·
Mar 29

Takeda's psoriasis pill succeeds in late-stage studies

Reuters
·
Mar 29

Pfizer Stock Eyes Rebound as Vaccine Bets Heat Up

TIPRANKS
·
Mar 28

Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus

Simply Wall St.
·
Mar 28

Income Investing: 6 Stocks Worth Buying That Yield More Than 5% -- Barron's

Dow Jones
·
Mar 28
More